Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xevinapant - Merck & Co

Next Previous
X
Search
Drug Profile

Xevinapant - Merck & Co

Alternative Names: AT 406; Debio-1143; SMAC mimetic - Debio-1143

Latest Information Update: 15 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascenta Therapeutics
  • Developer 3SBio; Ascenta Therapeutics; Debiopharm; EMD Serono; Merck & Co; The Leukemia & Lymphoma Society
  • Class Amides; Antineoplastics; Aza compounds; Benzene derivatives; Pyrroles; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Squamous cell cancer
  • Phase I Glioma
  • Discontinued Acute myeloid leukaemia; Adenocarcinoma; Leukaemia; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 04 Dec 2024 EMD Serono Research & Development Institute in collaboration with H. Lee Moffitt Cancer Center and Research Institute withdrew a phase I trial in Glioma in USA prior to enrolment due to funding issues (NCT06463184)
  • 27 Aug 2024 Suspended - Phase-II for Squamous cell cancer (Late-stage disease, Adjuvant therapy) in Norway, Slovenia, Ireland (PO) (NCT05724602)
  • 27 Aug 2024 Merck & Co suspends a phase II trial in Squamous cell cancer (Late-stage disease, Adjuvant therapy) in Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom (PO) (NCT05724602)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top